Deficient Drug Trial Caused Stock Drop, Ampio Investor Says
Ampio Pharmaceuticals Inc. misled investors into believing that its arthritis treatment was going to be approved by the U.S. Food and Drug Administration, causing shares to drop when the company disclosed...To view the full article, register now.
Already a subscriber? Click here to view full article